QIAGEN N.V. (QGEN)
Qiagen: New Launches Signal A Turnaround
Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation.
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
Qiagen N.V. (QGEN) Discusses Digital PCR Technology and Applications in Environmental Sample Analysis Transcript
QIAGEN Expands QIAcuity Gene Expression Portfolio to Drive dPCR Use
QGEN's QIAcuity expansion adds gene expression assays, multiplexing, automation and analysis tools to drive dPCR adoption.
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?
QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.
QIAGEN Business Breakdown and Growth Drivers for 2026
QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
QGEN's new QIA Agent platform uses conversational AI to streamline experiment planning and ordering support.
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Qiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Deciphering Qiagen (QGEN) International Revenue Trends
Examine Qiagen's (QGEN) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing Transcript
Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing Transcript
Qiagen (QGEN) Q1 Earnings and Revenues Lag Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.58 per share a year ago.
Qiagen (QGEN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
